Remove tag health-outcomes
article thumbnail

STAT+: CMS will use outcomes-based agreements in bid to help Medicaid pay for sickle cell gene therapies

STAT

In response to concerns over multimillion-dollar price tags for new gene therapies for sickle cell disease, the U.S. Two therapies recently approved by health regulators cost $2.2 Estimates vary, but the federal government believes as many as 60% of people with sickle cell disease rely on Medicaid for health care coverage.

138
138
article thumbnail

Revolutionizing Medicine and Public Health: The Emergence of Big Data in Healthcare

Roots Analysis

Velocity: Big Data needs to be handled promptly as businesses generate data at an unprecedented speed, driven by the growing adoption of Internet of Things (IoT), and technologies, such as RFID tags, sensors, and smart meters are used to deal with the high velocity of data in real-time. It is loosely arranged into categories using meta tags.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

ICER says bluebird bio’s $2.1m gene therapy is cost-effective

pharmaphorum

million price tag. million if paid through an outcomes-based contract for patients with sustained transfusion independence.” US cost-effectiveness watchdog ICER has handed bluebird bio some good news ahead of its FDA advisory committee meeting for rare blood disorder gene therapy beti-cel in June, by endorsing its proposed $2.1

FDA 62
article thumbnail

FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tag

pharmaphorum

ICER argues that Aduhelm was effectively approved on the strength of a biomarker – removing amyloid from the brain – rather than clinical outcomes, which is “puzzling” as other drugs have been shown to remove amyloid from the brain yet failed to help patients. Patrizia Cavazzoni (@FDACDERDirector) June 7, 2021. billion in 2027.

FDA 98
article thumbnail

What can pharma marketing learn from other regulated industries?

pharmaphorum

In this article Joanna Carlish, managing director of financial services at Tag Americas , and Robb DeFilippis, Tag Americas’ managing director, life sciences, go head-to-head to discuss marketing within a regulated industry. Joanna Carlish, managing director, financial services, Tag Americas. Virtual connections.

article thumbnail

3 ways pharma marketers can draw inspiration from digitally-native brands

pharmaphorum

“Digitally native brands are typically agile businesses from the ground up, and agility and flexibility are part of their core makeup,” says Joe Holmes, vice president, marketing services, US at Tag. Jeremy Richter, Tag. Joe began his life at Tag in the UK, bringing efficiencies to his clients, working across all conceivable channels.

article thumbnail

Patient adherence – the key to restoring trust in pharma

pharmaphorum

This lack of trust in such a crucial industry can lead to decreased compliance, poor treatment adherence, and negative health outcomes for patients. Given the high price tags placed on many medications, it’s easy to understand why patients often feel that they are being taken advantage of.